PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Curr Opin Pharmacol. Author manuscript; available in PMC 2010 August 1.
Published in final edited form as:
PMCID: PMC2731001
NIHMSID: NIHMS128876

Current and Potential Inflammation Targeted Therapies in Head and Neck Cancer

Abstract

Inflammation often exists in the tumor microenvironment and is induced by inflammatory mediators (cytokines, chemokines, and growth factors) produced by the tumor, stroma, and infiltrating cells. These factors modulate tissue remodeling and angiogenesis and actively promote tumor cell survival and chemoresistance through autocrine and paracrine mechanisms. Head and neck squamous cell carcinomas (HNSCCs) are highly inflammatory and aggressive in nature, and they express a number of cytokines and growth factors involved in inflammation. These cytokines and growth factors activate important signal transduction pathways, including NF-κB, JAK/STAT, and PI3K/Akt/mTOR, which regulate the expression of genes controlling growth, survival, and chemosensitivity. This review provides an update on recent advances in the understanding of the mechanisms driving cancer-related inflammation in HNSCC and on molecular targeted therapies under pre-clinical and clinical investigation.

Keywords: Inflammation, cytokines, signal pathways, targeted therapies, head and neck cancer

Background

Introduction

Head and neck squamous cell carcinoma (HNSCC) ranks among the 8 most common cancers in the world and is a significant cause of cancer morbidity and mortality. Approximately 35,000 new cases are diagnosed and 7,600 deaths occur annually in the United States alone [1]. Despite advances in treatment, the overall five-year survival rate has improved marginally over the past 40 years and remains relatively low at approximately 60% [1]. Tobacco and alcohol consumption, betel nut chewing, and human papillomavirus (HPV) infection are the most commonly cited risk factors for the development of HNSCC, and while our knowledge of the mechanisms driving transformation is incomplete, these conditions contribute to increased pro-inflammatory cytokine expression and aberrant signaling through inflammatory pathways [2,3]. Here, we briefly review the cytokines and inflammatory signal pathways that have been implicated in the development of HNSCC and discuss molecular therapeutics that have been used to target these pathways in the pre-clinical and clinical setting.

Aberrant expression of inflammatory cytokines and activation of signaling pathways in HNSCC

Cytokines regulate immunity, inflammation, and hematopoiesis, and this family of proteins includes interleukins (ILs), interferons (IFNs), tumor necrosis factors (TNFs), and growth factors [4]. They are typically divided into two categories: pro-inflammatory (e.g. IL-1, IL-6, IL-8, TNF-α, IFN-γ) and anti-inflammatory (e.g. IL-4, IL-10, TGF-β, and VEGF) [4]. They bind to receptors and transduce signals via second messengers to control growth, differentiation, and activation of cells [4].

Altered expression of cytokines and growth factors plays a major role in the malignant transformation of many cancers including HNSCC [5,6]. A number of such factors are found in HNSCC cell lines in vitro as well as in patients’ tumor specimens and serum. These include IL-1α, IL-6, IL-8, granulocyte-macrophage colony-stimulating factor (GM-CSF), GRO1, vascular endothelial growth factor (VEGF) [79], and hepatocyte growth factor (HGF) [10]. Decreasing cytokine and growth factor levels are associated with response to therapy, while increasing levels are related to cancer progression and recurrence [9]. A longitudinal increase in serum levels of these factors is significantly associated with decreased survival in patients who had local-regionally advanced oropharyngeal HNSCC undergoing chemotherapy and radiation [9]. IL-6 increases VEGF expression and the invasive potential in cell lines [11], and its expression correlates with poor prognosis in HNSCC patients [12]. IL-8 and GRO1 serve as chemoattractants for neutrophils, monocytes, and endothelial cells, which are all major constituents of the inflammatory and angiogenesis response, and their expression promotes aggressive growth and metastasis [13]. In addition, IL-1 and IL-6 are potent inducers of HGF production by stromal cells, such as fibroblasts, and HGF is capable of further enhancing IL-8 and VEGF expression [10]. Several cytokines and growth factors also activate signal pathways that promote the malignant phenotype. TNF-α, IL-1, HGF, and their receptors promote activation of the mitogen activated protein kinase-activator protein-1 (MAPK-AP-1), nuclear factor-kappa B (NF-κB), and phosphotidylinositol-3 kinase (PI3K)/Akt pathways [13]. Epidermal growth factor (EGF) and IL-6 activate signal transducer and activating transcription factor-3 (STAT3) in HNSCC cells (Fig. 1) [7,14,15].

Figure 1
Pharmacological inhibition of inflammatory signal pathways. Dysregulation of NF-κB (green), PI3K/Akt/mTOR (pink), and JAK/STAT (blue) signaling as well as PGE2 synthesis (yellow) contribute to inflammation seen in HNSCC as described in this review. ...

Aberrant activation of NF-κB and related pathways

NF-κB, an injury signal transcription factor, is activated in many cancers and contributes to cell survival, proliferation, invasion, inflammation, and angiogenesis (Fig. 1) [13, 16]. NF-κB1 (p105/p50), NF-κB2 (p100/p52), RelA (p65), c-Rel, and RelB comprise the NF-κB family. These proteins form dimers and in the absence of signal are bound to inhibitor-κBs (IκBs), which sequester these proteins in an inactive form within the cytoplasm. Upon activation by pro-inflammatory cytokines, such as IL-1 and TNF-α, IκB kinases (IKKs) and Casein kinase 2 (CK2) can phosphorylate IκBs, which leads to ubiquitination and degradation of the IκBs by the 26S proteasome. This releases the bound NF-κB1/RelA and allows for its processing and translocation to the nucleus, resulting in the activation of multiple target genes [16].

Constitutive activation of NF-κB dysregulates genes that regulate cell proliferation (cyclin D1), apoptosis and resistance to chemotherapeutics and radiation (IL-6, IL-8, cIAP1, Bcl-xL, YAP1), angiogenesis, immune, and proinflammatory responses (IL-6, IL-8, VEGF, HGF), and metastasis (IL-8, HGF, MMP9) [3,7,8,10,15,17,18]. Nuclear staining of the phospho-activated form of p65 increases with the stage of HNSCC, and upregulation of phosphorylated p65 correlates with decreased survival [13].

Blocking NF-κB function in HNSCC greatly reduces tumor growth and decreases the expression of IL-6 and IL-8 along with many other cytokines and chemokines associated with the pro-inflammatory state [7,8,13,15]. Experiments demonstrating this phenomenon include overexpression of an IκBα with S32/S36 phosphorylation site mutations (IκBαM) unresponsive to IKK phosphorylation, expression of kinase-dead mutants of IKK1 and IKK2 subunits [19, 20], and inhibition of CK2 kinase activity with apigenin and siRNA targeting CK2β [20]. Knockdown of p65 inhibits the expression of downstream NF-κB target genes, such as IL-6, IL-8 and YAP1, and results in the induction of cell death [8].

Recently, evidence for cross-talk between NF-κB and p53 in HNSCC has been obtained. Using genome-wide cDNA microarray profiling in a panel of HNSCC cell lines, unique gene signatures that distinguish subsets based on the mutation status of p53 were found [8]. Cell lines with minimal or weak TP53 expression exhibited strong expression of NF-κB target genes (IL-6, IL-8, cIAP1), and nuclear staining of activated p65 (phosphorylated at Ser536) was inversely related to p53 staining [8]. In addition, ΔNp63, a p53 family member, was found to form a novel complex with NF-κB subunit cRel to down-modulate p21 and promote growth [21]. Agents that inhibit NF-κB and promote re-expression of inactivated p53 have been identified, including aminoacridines, such as quinacrine [22,23], but their mechanism of action and suitability as oral or intravenous clinical agents remain unclear.

Reactive oxygen species (ROS) and reactive nitrogen species (RNS) may also play a role in the pathogenesis of HNSCC [24]. Loss of functional p53 has been implicated in the generation of ROS that may drive inflammatory gene expression mediated by NF-κB and propagation of genomic instability. Sablina et al. demonstrated that p53 maintains an important antioxidant function [25]. In addition, a variety of cell types from TP53 knockout mice, which are prone to tumor formation, have an increase in ROS, DNA damage, and mutagenesis. Antioxidants, such as tempol, have demonstrated potential in delaying onset of malignancy and prolonging survival in such tumor prone mice [26] but have yet to be developed and tested clinically.

Overexpression and autocrine activation of EGF receptor (EGFR) are detected in 90% of HNSCC. EGFR can activate the PI3K/Akt and mitogen-activated/extracellular signal-regulated kinase (MEK) pathways, which modulate activation of NF-κB and AP-1 and induce proinflammatory and proangiogenic IL-8 and VEGF expression [7,27]. Akt kinase contributes to NF-κB activation and also activates mammalian target of rapamycin (mTOR), a kinase important in initiating synthesis of inflammatory and angiogenic proteins induced by NF-κB, hypoxia inducible factor (HIF-1α), and VEGF (Fig. 1) [28]. Rapamycin and synthetic mTOR inhibitors have demonstrated significant antitumor activity in vivo in preclinical animal models [29,30]. EGFR and IL-6 have both been shown to activate STAT3 (Fig. 1), and the relative role of these ligands and their receptors may depend on epigenetic inactivation of SOCS-1, a gene involved in negative feedback of IL-6R-janus kinase-mediated STAT3 activation [7,15]. Both promote expression of genes important in proliferation and cell survival via STAT3 in coordination with AP-1 and NF-κB. Thus, it may not be surprising that using EGFR inhibitors alone have shown limited activity in only ~10% of patients with HNSCC [27,31].

Prostaglandins and COX2 in HNSCC

Prostaglandins have been found to be increased in HNSCC, and one of the most important members, prostaglandin E2 (PGE2), promotes growth, inhibits apoptosis by upregulating Bcl-2 expression, increases the production of angiogenic factors, and promotes invasiveness and metastatic growth [32]. The cyclooxygenase (COX) enzymes facilitate the synthesis of prostaglandins. COX-1 and COX-2 are the two isoforms found in humans. COX-1 is present in most tissues, but COX-2 is usually over-expressed in inflammation and in pre-neoplastic lesions and tumors, consistent with its regulation as another target gene of NF-κB (Fig. 1). Higher expression of COX-2 in tumor cells is seen in conjunction with increased PGE2 levels in HNSCC, suggesting that COX-2 may be a rate-limiting step in the formation of PGE2. The level of COX-2 expression in HNSCC has prognostic value, and selective inhibitors of COX-2 inhibit HNSCC and increase the effectiveness of radiotherapy in vitro [32].

Therapeutics Targeting Inflammation in HNSCC

The increased expression of inflammatory mediators in HNSCC suggests that blocking these pathways could play an important role in treating these cancers in conjunction with drugs that target other pathways that contribute to the global phenotype of HNSCC (Fig. 1, Table 1).

Table 1
Summary of drugs targeting inflammation and their clinical status.

Immunological blockade of cytokines

Preclinical studies indicate that TNF-α and IL-1, pro-inflammatory cytokines that potentiates the activation of NF-κB, contribute to tumorigenesis. Anakinra is an IL-1RA that has been studied clinically. IL-1 receptor antagonist (IL-1RA) expressed intracellularly can block IL-1 mediated signal activation of NF-κB, although a recombinant IL-1RA did not have significant activity [13]. Anti-TNF-α antibodies infliximab and etanercept demonstrated antitumor effects in pancreatic cell lines in vitro and significantly reduced primary tumor burden and number of liver metastases in mouse models in vivo (Fig. 1) [33,34]. While monoclonal antibodies against TNF-α have been studied in clinical trials as therapeutic agents in a number of chronic inflammatory disorders, their study in cancer has been limited. Tocilizumab, a monoclonal antibody against IL-6, is currently under evaluation in chronic inflammatory diseases and may be of interest for studies in HNSCC as well [35].

Targeting NF-κB and related pathways

Several agents have been studied that inhibit the activation of NF-κB. Bortezomib, a boronic dipeptide that inhibits the catalytic site of the 26S proteasome, inhibits the degradation of IκBα and the nuclear translocation and activation of canonical subunits of NF-κB, p65 and p50, and induces cell death in HNSCC cell lines and murine xenograft models (Fig. 1) [36]. Clinical trials in patients with HNSCC using this drug show inhibition of nuclear p65 and enhanced apoptosis, but its use in combination with re-irradiation has demonstrated limited clinical responses (Table 1) [18]. It is currently undergoing clinical trials in combination with other chemotherapeutics, including cetuximab, cisplatin, docetaxel, doxorubicin, gemcitabine, irinotecan, and with radiation [37]. IKKβ inhibitors have been a major subject for more specific targeting of NF-κB activation, but evidence that IKKα and IKKβ both contribute to NF-κβ activation may explain the limited activity of IKKβ agents found in HNSCC in pre-clinical studies [19,20].

Geldanomycins are natural inhibitors of heat shock protein 90kD (HSP90), a chaperone of IKK and Akt involved in NF-κB and mTOR activation (Fig. 1) [38]. They exhibit cytotoxic activity in a number of cancers but have demonstrated significant toxicity in clinical trials [38]. Synthetic HSP90 inhibitors with wider therapeutic window in preclinical studies (e.g. SNX-5422, IPI-504) are under clinical investigation.

Curcumin, a naturally occurring polyphenol, inhibited NF-κB as demonstrated by impairment of IKK activation and nuclear translocation and DNA binding (Fig. 1) [39]. Phase I studies using this drug have highlighted the lack of toxicity even when given in large doses and showed potent anti-inflammatory effects demonstrated by reduced inducible PGE2 levels in the blood [40]. Phase II trials in pancreatic cancer documented poor bioavailability with oral administration but reported reduction in tumor burden in two out of 21 patients. Even with low serum levels of curcumin, expression levels of NF-κB, COX-2, and STAT-3 in peripheral blood mononuclear cells were found to be downregulated, indicating that facilitation of bioavailability could potentially improve outcomes [41]. Early results from a clinical trial studying the effects of oral administration of curcumin in oral premalignant lesions have shown histologic improvement in 29% of patients within 3 months of treatment [42].

mTOR inhibitors

mTOR has been classically described as a downstream target of oncogenic Akt signaling. Akt-independent activation of mTOR also occurs in response to treatment with inflammatory cytokines like TNF-α, which is mediated through IKKα [43]. Preclinical studies using rapamycin to inhibit mTOR signaling (Fig. 1) have been promising. The drug, administered to mice with cancerous and pre-cancerous oral lesions induced with 4-Nitroquinoline 1-oxide (4NQ), prevented premalignant lesions from progressing to squamous carcinoma and reduced the size of cancerous lesions [44]. Success with mTOR inhibition strategies in cancer cell types from diverse sites is reflected in a number of ongoing trials using mTOR inhibitors, both alone and as adjuvant treatment, for advanced cancers.

EGFR and STAT3 inhibitors

Cetuximab, a monoclonal antibody against EGFR, and gefitinib, an inhibitor of EGFR tyrosine kinase, have been used clinically to block downstream EGFR signaling in HNSCC. Used as a single agent or in combination with chemotherapy or radiation, gefitinib has shown limited efficacy with a response rate of ~10–15% in clinical trials in HNSCC [45]. In a phase I trial of gefitinib combined with paclitaxel and radiation for patients with locoregionally advanced HNSCC, resistance to gefitinib was associated with STAT3 overexpression and activation but not with EGFR phosphorylation or mutation [27,31]. In addition, STAT3 decoy oligonucleotides have demonstrated inhibition of STAT3, angiogenesis, and tumor activity in preclinical models, and a STAT3 decoy phase I trial is underway [14]. Since STAT3 is activated by EGFR and IL-6R, EGFR inhibition in combination with IL-6 antagonists [7] or STAT decoy oligonucleotides [46] holds potential for synergistic activity.

Targeting the COX-2/PGE2 pathway

COX-2 is overexpressed in oral premalignant lesions (OPL) and in HNSCC, and this is correlated with decreased apoptosis and increased angiogenesis and invasiveness [47]. However, clinical trials using non-steroidal anti-inflammatory drugs (NSAIDs) to inhibit COX-2 have not been very successful in chemoprevention of OPL and HNSCC. Ketorolac, a COX-1 and COX-2 inhibitor, failed to demonstrate any significant reduction in oral leukoplakia compared to placebo when administered as an oral rinse [48]. Celecoxib, a specific inhibitor of COX-2, was ineffective in controlling oral premalignant lesions, and accumulating evidence of cardiotoxicity in these drugs has limited the investigation of these drugs as primary chemoprevention agents [49]. There are several trials in progress that are studying the benefit of celecoxib for prevention of recurrence in high-risk patients with head and neck cancer [50].

Conclusion

The role of inflammation in head and neck cancer has been studied quite extensively at the molecular level, but there are still many questions left to be answered. Dysregulation of inflammatory responses in cancer perpetuates the malignant phenotype, and many pharmacological interventions have been developed to target inflammatory mediators and signal pathways. However, only a few of these promising pharmacologic interventions have been tested or proven to be efficacious in treating patients with HNSCC in clinical trials. Most researchers are now studying therapies that act in combination with other targeted agents or conventional chemotherapy and radiation treatments with the hope that attacking multiple pathways in these tumors will disrupt the malignant programming of the cells and inhibit the pro-survival signals, resulting in significant clinical activity. Based on evidence for co-activation of MAPK-AP-1, IKK-NF-κB, and JAK-STAT3 pathways, small molecule inhibitors targeting these kinases or upstream ligands and receptors would seem to merit investigation for combined therapy. Also of interest are several natural or synthetic products that act concurrently on IKK, Akt, NF-κB, and p53, but the efficacy of these drugs has yet to be developed fully for clinical use in HNSCC.

Acknowledgments

Supported by NIDCD intramural projects Z01-DC-000016 and Z01-DC-000073, and Howard Hughes Medical Institute-National Institutes of Health Research Scholars Program (FW).

Footnotes

Disclosures: The corresponding author (CVW) has an NIH Material Cooperative Research and Development Agreement with Millennium Pharmaceuticals for proteasome and Inhibitor-kappaB Kinase inibitors, and Pfizer for HSP90 inhibitors.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics. CA Cancer J Clin. 2008;58(2):71–96. [PubMed]
2. Allen CT, Ricker JL, Chen Z, Van Waes C. Role of activated nuclear factor-kappaB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck. Head Neck. 2007;29(10):959–971. [PubMed]
3•. Molinolo AA, Amornphimoltham P, Squarize CH, Castilho RM, Patel V, Gutkind JS. Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol. 2008 A review highlighting the importance of signal networks in pathogenesis of HNSCC and need for targeting pathways with multiple agents. [PMC free article] [PubMed]
4. Serefoglou Z, Yapijakis C, Nkenke E, Vairaktaris E. Genetic association of cytokine DNA polymorphisms with head and neck cancer. Oral Oncol. 2008;44(12):1093–1099. [PubMed]
5. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–444. [PubMed]
6. Pries R, Nitsch S, Wollenberg B. Role of cytokines in head and neck squamous cell carcinoma. Expert Rev Anticancer Ther. 2006;6(9):1195–1203. [PubMed]
7. Lee TL, Yeh J, Van Waes C, Chen Z. Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas. Mol Cancer Ther. 2006;5(1):8–19. [PubMed]
8•. Lee TL, Yang XP, Yan B, Friedman J, Duggal P, Bagain L, Dong G, Yeh NT, Wang J, Zhou J, Elkahloun A, et al. A novel nuclear factor-kappaB gene signature is differentially expressed in head and neck squamous cell carcinomas in association with TP53 status. Clin Cancer Res. 2007;13(19):5680–5691. This is the first study to demonstrate an interaction between TP53 status and activation of NF-κB and proinflammatory and prosurvival genes in HNSCC. [PubMed]
9••. Allen C, Duffy S, Teknos T, Islam M, Chen Z, Albert PS, Wolf G, Van Waes C. Nuclear factor-kappaB-related serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal carcinoma. Clin Cancer Res. 2007;13(11):3182–3190. Demonstrates proinflammatory cytokines can be used as markers of treatment response and recurrence. [PubMed]
10. Worden B, Yang XP, Lee TL, Bagain L, Yeh NT, Cohen JG, Van Waes C, Chen Z. Hepatocyte growth factor/scatter factor differentially regulates expression of proangiogenic factors through Egr-1 in head and neck squamous cell carcinoma. Cancer Res. 2005;65(16):7071–7080. [PubMed]
11. Kanazawa T, Nishino H, Hasegawa M, Ohta Y, lino Y, Ichimura K, Noda Y. Interleukin-6 directly influences proliferation and invasion potential of head and neck cancer cells. Eur Arch Otorhinolaryngol. 2007;264(7):815–821. [PubMed]
12. Duffy SA, Taylor JM, Terrell JE, Islam M, Li Y, Fowler KE, Wolf GT, Teknos TN. Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer. 2008;113(4):750–757. [PubMed]
13. Van Waes C. Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin Cancer Res. 2007;13(4):1076–1082. [PubMed]
14. Leeman RJ, Lui VW, Grandis JR. STAT3 as a therapeutic target in head and neck cancer. Expert Opin Biol Ther. 2006;6(3):231–241. [PubMed]
15. Lee TL, Yeh J, Friedman J, Yan B, Yang X, Yeh NT, Van Waes C, Chen Z. A signal network involving coactivated NF-kappaB and STAT3 and altered p53 modulates BAX/BCL-XL expression and promotes cell survival of head and neck squamous cell carcinomas. Int J Cancer. 2008;122(9):1987–1998. [PubMed]
16. Brown M, Cohen J, Arun P, Chen Z, Van Waes C. NF-kappaB in carcinoma therapy and prevention. Expert Opin Ther Targets. 2008;12(9):1109–1122. [PMC free article] [PubMed]
17. Duan J, Friedman J, Nottingham L, Chen Z, Ara G, Van Waes C. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101. Mol Cancer Ther. 2007;6(1):37–50. [PubMed]
18. Allen C, Saigal K, Nottingham L, Arun P, Chen Z, Van Waes C. Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer. Clin Cancer Res. 2008;14(13):4175–4185. [PubMed]
19. Van Waes C, Yu M, Nottingham L, Karin M. Inhibitor-kappaB kinase in tumor promotion and suppression during progression of squamous cell carcinoma. Clin Cancer Res. 2007;13(17):4956–4959. [PubMed]
20. Yu M, Yeh J, Van Waes C. Protein kinase casein kinase 2 mediates inhibitor-kappaB kinase and aberrant nuclear factor-kappaB activation by serum factor(s) in head and neck squamous carcinoma cells. Cancer Res. 2006;66 (13):6722–6731. [PMC free article] [PubMed]
21••. King KE, Ponnamperuma RM, Allen C, Lu H, Duggal P, Chen Z, Van Waes C, Weinberg WC. The p53 homologue DeltaNp63alpha interacts with the nuclear factor-kappaB pathway to modulate epithelial cell growth. Cancer Res. 2008;68(13):5122–5131. First paper to demonstrate a novel transcription factor formed by member of TP53 and NF-κB family, which modulates cell growth (and cytokine expression) [PMC free article] [PubMed]
22. Gurova KV, Hill JE, Guo C, Prokvolit A, Burdelya LG, Samoylova E, Khodyakova AV, Ganapathi R, Ganapathi M, Tararova ND, Bosykh D, et al. Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci U S A. 2005;102(48):17448–17453. [PubMed]
23. Friedman J, Nottingham L, Duggal P, Pernas FG, Yan B, Yang XP, Chen Z, Van Waes C. Deficient TP53 expression, function, and cisplatin sensitivity are restored by quinacrine in head and neck cancer. Clin Cancer Res. 2007;13 (22 Pt 1):6568–6578. [PubMed]
24. Rasheed MH, Beevi SS, Geetha A. Enhanced lipid peroxidation and nitric oxide products with deranged antioxidant status in patients with head and neck squamous cell carcinoma. Oral Oncol. 2007;43(4):333–338. [PubMed]
25. Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE, Chumakov PM. The antioxidant function of the p53 tumor suppressor. Nat Med. 2005;11(12):1306–1313. [PMC free article] [PubMed]
26. Zhang QS, Eaton L, Snyder ER, Houghtaling S, Mitchell JB, Finegold M, Van Waes C, Grompe M. Tempol protects against oxidative damage and delays epithelial tumor onset in Fanconi anemia mice. Cancer Res. 2008;68(5):1601–1608. [PubMed]
27. Pernas FG, Allen CT, Winters ME, Dabir B, Saigal K, Mundinger GS, Yan B, Friedman J, Xu X, Morris JC, Calvo KR, et al. Proteomic signatures and responses of epitermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer. Clin Cancer Res. 2009 (in press) [PubMed]
28. Ricker JL, Chen Z, Yang XP, Pribluda VS, Swartz GM, Van Waes C. 2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma. Clin Cancer Res. 2004;10(24):8665–8673. [PubMed]
29. Amornphimoltham P, Patel V, Sodhi A, Nikitakis NG, Sauk JJ, Sausville EA, Molinolo AA, Gutkind JS. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Cancer Res. 2005;65 (21):9953–9961. [PubMed]
30. Nathan CO, Amirghahari N, Rong X, Giordano T, Sibley D, Nordberg M, Glass J, Agarwal A, Caldito G. Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer. Cancer Res. 2007;67(5):2160–2168. [PubMed]
31. Van Waes C, Allen C, Citrin D, Colevas AD, Harold N, Rudy S, Muir C, Chen Z, Singh AK, Albert P, Dancy J, et al. Molecular and clinical responses in a phase I study of gefitinib combined with paclitaxel and radiation in patients with locally advanced head and neck cancers. Int J Rad Oncol Biol Phys. 2009 (in press)
32. Camacho M, Leon X, Fernandez-Figueras MT, Quer M, Vila L. Prostaglandin E(2) pathway in head and neck squamous cell carcinoma. Head Neck. 2008;30 (9):1175–1181. [PubMed]
33••. Egberts JH, Cloosters V, Noack A, Schniewind B, Thon L, Klose S, Kettler B, von Forstner C, Kneitz C, Tepel J, Adam D, et al. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res. 2008;68(5):1443–1450. Demonstrates potential of inhibition of TNF, a cytokine activator of NF-κB, in pancreatic cancer. [PubMed]
34. Zidi I, Mestiri S, Bartegi A, Amor NB. TNF-alpha and its inhibitors in cancer. Med Oncol. 2009 [PubMed]
35. Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol. 2006;2(11):619–626. [PubMed]
36•. Chen Z, Ricker JL, Malhotra PS, Nottingham L, Bagain L, Lee TL, Yeh NT, Van Waes C. Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms. Mol Cancer Ther. 2008;7(7):1949–1960. Demonstrates limited activity of proteasome inhibition in patients may be explained by alternative NF-kB as well as STAT3 and MAPK activation. [PMC free article] [PubMed]
37. National Cancer Institute. ClinicalTrials.gov [Internet] Bethesda (MD): National Library of Medicine (US); 2007. [cited 2009 Feb 19]. Phase I study of bortezomib and cetuximab without or with cisplatin in combination with radiation therapy for advanced head and neck cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT00629226 NLM Identifier: NCT00629226.
38. Messaoudi S, Peyrat JF, Brion JD, Alami M. Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem. 2008;8(7):761–782. [PubMed]
39. Aggarwal S, Takada Y, Singh S, Myers JN, Aggarwal BB. Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-kappaB signaling. Int J Cancer. 2004;111(5):679–692. [PubMed]
40. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res. 2004;10(20):6847–6854. [PubMed]
41•. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V, Kurzrock R. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008;14(14):4491–4499. Trial demonstrates activity of curcumin in pancreatic carcinoma, and inhibitor of NF-κB, despite poor bioavailability. [PubMed]
42. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB. Curcumin and cancer: an “old-age” disease with an “age-old” solution. Cancer Lett. 2008;267(1):133–164. [PubMed]
43. Dan HC, Baldwin AS. Differential involvement of IkappaB kinases alpha and beta in cytokine- and insulin-induced mammalian target of rapamycin activation determined by Akt. J Immunol. 2008;180(11):7582–7589. [PubMed]
44•. Czerninski R, Amornphimoltham P, Patel V, Molinolo AA, Gutkind JS. Targeting mammalian target of rapamycin by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model. Cancer Prev Res (Phila Pa) 2009;2(1):2736. Demonstrates potential of mTOR inhibitors which block translation of inflammatory and angiogenesis factors to inhibit HNSCC. [PubMed]
45. Loeffler-Ragg J, Schwentner I, Sprinzl GM, Zwierzina H. EGFR inhibition as a therapy for head and neck squamous cell carcinoma. Expert Opin Investig Drugs. 2008;17(10):1517–1531. [PubMed]
46•. Sen M, Tosca PJ, Zwayer C, Ryan MJ, Johnson JD, Knostman KA, Giclas PC, Peggins JO, Tomaszewski JE, McMurray TP, Li C, et al. Lack of toxicity of a STAT3 decoy oligonucleotide. Cancer Chemother Pharmacol. 2008 A novel oligonucleotide based inhibitor of STAT3 in clinical trial. [PMC free article] [PubMed]
47. Lin DT, Subbaramaiah K, Shah JP, Dannenberg AJ, Boyle JO. Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer. Head Neck. 2002;24(8):792–799. [PubMed]
48•. Mulshine JL, Atkinson JC, Greer RO, Papadimitrakopoulou VA, Van Waes C, Rudy S, Martin JW, Steinberg SM, Liewehr DJ, Avis I, Linnoila RI, et al. Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin Cancer Res. 2004;10(5):1565–1573. A negative controlled study regarding activity of COX inhibitors as an oral rinse. [PubMed]
49. Papadimitrakopoulou VA, William WN, Jr, Dannenberg AJ, Lippman SM, Lee JJ, Ondrey FG, Peterson DE, Feng L, Atwell A, El-Naggar AK, Nathan CA, et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res. 2008;14(7):2095–2101. [PubMed]
50. Centre Hospitalier Universitaire Vaudois. ClinicalTrials.gov [Internet] Bethesda (MD): National Library of Medicine (US); 2006. [cited 2009 Feb 19]. Celecoxib in treating patients with head and neck cancer that can be removed by surgery. Available from: http://clinicaltrials.gov/ct2/show/NCT00357617 NLM Identifier: NCT00357617.